Tuberculosis has long been managed through patient persistence with daily pills over many months, a burden that quietly defeats many who begin treatment. On 28 October 2026 the World Health Organization offered a new kind of answer: a set of target profiles telling those who might build long-acting injectable TB medicines what success must look like. One injection to prevent the disease, and treatment finished in four months or less with three visits at most, now stand as the measures against which early candidates will be judged. The aim is less a promise of cures than a shared horizon, one t
WHO Sets Target Profiles for Long-Acting TB Injectables to Ease Months-Long Treatment
One injection to prevent TB, and no more than four months to treat it
Mark
Why does a document of targets matter before any product exists?
Mimi
Because it tells developers early what counts as worth pursuing. Each characteristic has a minimal and an optimal requirement, so a product that can't meet the minimum isn't worth the investment.
Mark
What are the headline targets?
Mimi
For prevention, a full course in a single injection at one encounter. For TB disease, no more than four months and three or fewer dosing encounters.
Luke
Those are targets, not results. Nothing here says any candidate can reach them.
Mimi
Fair. The source says candidates are entering or approaching clinical development, not that any has shown it works.
Mark
What else is required beyond fewer doses?
Mimi
Injections by a trained health worker at the lowest feasible level of care, small volumes, no cold chain, and efficacy and safety at least as good as oral regimens.
Luke
And who shaped this? Is it just industry talking?
Mimi
The development group included trialists, pharmacologists, regulators, national programme officers, people with lived experience of TB and civil society. They also ran a public consultation in April and May 2026 and a multicountry discrete choice experiment.
Luke
The source doesn't give the results of those surveys, so I can't say how much they moved the numbers.
Mark
Does this replace pills?
Mimi
No. WHO says oral regimen work should continue for people who prefer not to have injections, and that patient choice should be preserved.
Le Pouls
- Months of daily pills have made tuberculosis treatment a grinding test of endurance for patients and health workers alike.
- WHO has published target profiles that set hard minimum and optimal bars for new long-acting TB injectables before they reach trials.
- Developers must now design preventive courses as a single injection and disease treatment within four months and three visits or fewer.
- Trial designers and industry are being handed these thresholds early, while oral regimen research continues for those who decline needles.
- The next signal to watch is how the first TB injectable candidates shape their clinical studies around these targets.
Tuberculosis has long been managed through patient persistence with daily pills over many months, a burden that quietly defeats many who begin treatment. On 28 October 2026 the World Health Organization offered a new kind of answer: a set of target profiles telling those who might build long-acting injectable TB medicines what success must look like. One injection to prevent the disease, and treatment finished in four months or less with three visits at most, now stand as the measures against which early candidates will be judged. The aim is less a promise of cures than a shared horizon, one that keeps patient choice and the familiar oral path open alongside it.
The World Health Organization has set out, in a document called Target regimen profiles for long-acting injectables, what a new generation of tuberculosis medicines should achieve before anyone spends years building them. Released on 28 October 2026, it asks for one injection to prevent TB and, for treatment, a course of four months or less delivered in three or fewer clinic visits.
The reason is familiar to anyone who has watched TB care up close. Prevention and treatment still depend on daily pills taken for months, and staying on that schedule is hard for many people. Long-acting injectables have already reshaped care for HIV, and several TB candidates are now approaching clinical development, so WHO is defining expectations early.
The profiles set two thresholds for each feature: a minimum a product must reach to be worth pursuing, and an optimal target that is still realistically within reach. Both call for injections given by trained health workers at the lowest practical level of the health system, in small volumes, without a cold chain, and with efficacy and safety at least equal to current oral regimens.
The document was shaped by a Scientific TRP Development Group that included trialists, pharmacologists, regulators, national programme officers, people who have lived with TB, and civil society representatives, along with consultations, surveys and focus groups. WHO is clear that injectables are not the only path: better oral regimens should keep advancing, and patients should keep the choice. What comes next is how the first candidates use these targets as they enter clinical studies.
The World Health Organization has put a set of numbers in front of the people who might build the next generation of tuberculosis drugs: one injection to prevent TB, and no more than four months and three clinic encounters to treat it. The targets come in a newly published document called Target regimen profiles for long-acting injectables, released on 28 October 2026.
The problem they address is an old one. TB prevention and treatment still rest on daily oral regimens that run for months, and keeping up with pills over that long a stretch is hard for many people. WHO's argument is that long-acting injectables, known as LAIs, could lighten the load both for the people taking the medicines and for the health systems that deliver them. Such injectables have already changed the management of other conditions, most visibly HIV. Several LAI candidates for TB are now entering or approaching clinical development, which is why WHO is setting expectations now.
The profiles, called TRPs, describe what a new LAI regimen would need to achieve to be useful in practice, and they do so early in development. For each characteristic, the document defines two thresholds: a minimal requirement, which a product must meet to be worth pursuing, and an optimal requirement, the most desirable target that is still realistically achievable. The intended audience is broad: the pharmaceutical industry, academia, research institutions, product development partners, TB-affected communities, civil society organizations and donors.
The two profiles differ in ambition. For TB preventive treatment, the aim is a full course delivered as a single injection at one encounter. For TB disease, the aim is a regimen of no more than four months, given in three or fewer dosing encounters. Both call for injections administered by a trained health worker at the lowest feasible level of the health system, in small volumes, without a cold chain. Both also require efficacy and safety at least as good as current oral regimens. The document goes on to lay out trade-offs between characteristics and to address trial design, overall treatment burden, scalability, equitable access, transparent pricing and cost.
Dr Tereza Kasaeva, Director of the WHO Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections, said the profiles tell developers early what a new regimen must achieve to make a real difference, without giving up efficacy, safety or patient choice. She said long-acting injectables could make TB prevention and treatment much simpler for those who need them.
WHO convened a Scientific TRP Development Group to write the profiles. Its members included trialists, pharmacologists, regulators, national TB programme officers, people with lived experience of TB, and civil society representatives. The group drew on a landscape analysis, a public consultation held in April and May 2026, and community and provider surveys. It also used focus group discussions and a multicountry discrete choice experiment.
The document is explicit that injectables are not the only path. Work on better oral regimens should continue in parallel, for people who would prefer not to receive injections, and implementation should preserve patient choice. What to watch next is how developers and trial designers use the minimal and optimal targets as the first TB LAI candidates move into clinical studies.
Citations marquantes
The profiles tell developers early what a new regimen must achieve to make a difference in practice, without trading away efficacy, safety or patient choice.— Dr Tereza Kasaeva, Director, WHO Department for HIV, Tuberculosis, Hepatitis and STIs
Envie de l'histoire complète ?
Lire l'original sur World Health Organization (WHO) ↗
Health & Medicine